Study of adebrelimab plus apatinib after liver cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is testing a combination of two drugs (adebrelimab and apatinib) after liver cancer surgery to see if it can lower the chance of the cancer returning. It is for people whose tumors had high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove your liver cancer within the last 4 to 12 weeks.
- You have a high risk of the cancer coming back after surgery (e.g., large or multiple tumors, or spread to blood vessels).
- You have not had any prior medications or infusions for liver cancer (except surgery).
- Your liver is working fairly well (Child-Pugh score A or B, less than 7 points).
- Your overall health is good enough for daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (Adebrelimab, an immunotherapy, plus Apatinib, a targeted therapy) for people with advanced liver cancer who have already tried other treatments. The goal is to see if this combination can help shrink or control the cancer.
This trial tests whether combining two drugs, camrelizumab (an immunotherapy) and apatinib (a targeted therapy), can prevent liver cancer from coming back in people who've had surgery or ablation to remove their tumor. It's for patients with a high risk of recurrence.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of three drugs (SHR-8068, Adebrelimab, and Apatinib) given before and after surgery for liver cancer that can be removed. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests giving a combination of two medications, adebrelimab (an immunotherapy) and apatinib (a targeted therapy), before surgery for people with stage II or III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This study looks at how well a combination of camrelizumab and apatinib works for people with unresectable hepatocellular carcinoma (liver cancer you can’t remove with surgery). It is designed to see results in real-life care for patients who have limited options after standard treatment.
Hear when a new Carcinoma, Hepatocellular trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.